Note: Descriptions are shown in the official language in which they were submitted.
~L~3~3~5~ ::
The present invention relates to ~n antibacterial
composition for animalsO More partlcularly, it relates to an
antibacterial composition comprising a cephalosporin com~ound
or it~ salt ~nd a penicillin compound or its salt.
Cephalosporin compounds an~ penicillin co~pounds-and
their salts have been known as antibiotics having a wide range
of antibacterial spectrum.
A~ the results of the extensive s-tudyings of the
pre3ent inventors~ it has been newly found ~hat some speci~
~ic cephalosporin compounds or their salts exhibit a synergis-
tic antibacterial activities by combining with some penicillin
compounds or their salts, th~t is, the combination of the ~ -
cephalosporin compounds or their salt with t'ne penicillin com-
pounds or their salts shows a strong antibacterial activity
-
against pathogenic bacteria in animals other than human,~par-
~ticularly gr~m-ne~ative bacteria such as Citrobacter and Proteus,
~against which the ceph~losporin compounds and penicillin com~
pounds show no or litt~e antibacterial activit~, when they are
u6ed each alone, and against the cephalosporin compounds- and
penicillin compounds-resistant bacteria.
- ~ An object of the present inven~ion i~ to provide an
antibacterial composition for animals comprisine a cephalo-
8porin compound or its salt an~ a penicillin compound or its
salt useful against pathogenic bacteria in animals, against
whiCh the cephalosporin compound or the penicillin compour.d
alone i3 not eff~ctive.
~ nothcr ob~ect o~ the invention is to provide an
antibacterlal composltion 40r animal~ useful a~ain~t the cephalo-
8porin co~pound- or penicillin co~pound-r~istant bacteria.
A further ob~ect OL th~ invent~on is to provide an
- 2 - ~ `
~3~7S~ :
antibacterial composition for nnimals having an excell0nt bac~
tericidal rate an~ enhanced therapeutic and preventive effects.
A still further object of the invention is to pro-
~ide an antibacterial compo~it~on u~eful for treating or pre~
venting animal disea~es induced by pathogenic bacteria, par-
ticularly ma~titi~ in cow or other animals.
These and other objects of the in~ention will be ;.
apparent from the description hereinafter.
: The antibacterial composition of the present inven~
tion comprises a combination o~ a cephalosporin compound o~
the formula~
., ~ ~' .
70 N 2 ~ ~
~_~" ~,L_-N \ ~ H2 ~-Rl .
- 1 . .-: .
- - ~OOH .
wherein ~ is a substituted or unsubstituted heterocyclic
group, or its salt and a penicillin compound of the formula~
S CH~
COOH
1-
wherein R2 is an acyl group, or its salt. . 1`
The heterocyclic group (Rl) in the above cephalo-
~porln compound (I) i~ a 5 or 6-membered heterocyclic group
including at lea~t one nitrogen atom and includes, for.e~ample.
thiadiazolyl, o~adiazolyl, thiazolyl and tetrazolyl which may
be substituted bg an alkyl group having 1 to 4 carbon atoms.
Preferred heterocyclic group i~ 1,3,4-thiadiazol-2-yl, 5-methyl-
~ 4-thiadiazol-2-yl, 5-methgl 1,3,4-oxadiazol-2-yl, 1,2,3-
triazol-4-yl, 1-methyl-1,3,4-triazol-2 yl and l-methyltetrazol-
5-yl. The tetrazolylacetamido.group at 7 position o~ cephalo-
_ ~ _
.. ..... . .. .
.. ..
. ~ , . .
~3~759
8porin compound (I) includes (tetrazol-1-yl)aoetamido and
(tetrazol-2-yl)acetamido
The ~alts of the cephalosporin compounds (I) include
~hysiologically acceptable salts, such as a metal salt (e.g.
sodium, potassium or calcium salt); ammonium salt, an amine
salt (e.g. trimethylamine, triethylamine, procaine or dibenzyl-
amine ~alt), a salt with a basic amino acid, or the like which
are a conventional salt of cephalosporin compounds.
Pre~erred examples of the cephalosporin compounds
(I) are 7-(tetrazol-l-yl)acetamido-3-(5-~ethyl~1,394-thla_
diazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid (i.e.
cefazolin), j-(tetrazol-l-yl)acetamido-3-(1,3,4-thiadiazo1-
2-yl)thiomethyl-3-cephem-4-carboxylic acid (hereinafter, re-
~erred to ss ~R-10123) and 7-(tetrazol-1-yl~acetam1do-3-
methyltetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid
(hereinafter, referrea to aæ FR-10675) and the1r salts. Among
such cephalosporir.s, cefasolin sodium is known æs~ni~ue anti-
biotics and marked world-widely.
The pen}cill1n compounds (II~ include natursl peni- ~
oillin~ and semi-synthetic penicillins. And, as ths acyl group
o~ the penicillin compounds (II), there are msntioned, ~or ex
amp-e, an alkanoyl and alkenyl ha~ing 2 to 8 carbon atoms which
may be æubstituted by amino, carbo~y or aryloxy whic~ may be
,
8ubstituted by hydroxy, halogen or nitro (e.g. 2-pentenylcarbonyl,
n-heptylcarbonyl, caproyl, 4-amino-4-carbo~ybutyryl, a-phenoxy-
butyryl, a-phenoxypropionyl or p-chlorophenoxyacetyl); a phenyl-
acetyl wherein the phenyl eroup may be substituted by hydroxy
or methoxy and the acetyl ~roup may be ~ubstituted by amino,
carboxy or 8u1~0 at the a-po8ition (e,g. phenylacetyl, p-hydroxy-
phenylacetyl, a-amino-(p-hydroxyphenyl)acetyl, a-~ulfo-phenyl
- 4
.... . . ............ . . . . . . .
,~' ' l!
. , .
759
acetyl, u-carboxy-phenyla~etyl, 2,6-dimethoxyphenylacetyl or
a~aminophenylacetyl) and a heterocyclic carbonyl wherein the
heterocyclic group may be ~ubstituted by a lower alkyl or aryl
wherein the aryl group may be ~ubstituted by a halogen (e.g.
(5-methyl-3-phenyl-isoxazol-4-yl)carbonyl7 [3-(o-chlorophenyl~
5-methylisoxazol-4~yl]carbonyl~ [3-(2,6-dichlorophenyl)-5
methyliso~azol-4~yl]carbonyl, (5-methyl-~-phenylisoxazol-4-
yl~carbonyl or [3-(6-~luoro~2-chlorophenyl)-5-methylisoxazol-
4-yl]carbonyl).
Representative examples o~ the natural penicillins
may be penicillin G, ~ X, penicillin F, penicillin
~, 3-pentenylpenicillin, dihydropenicillin F, penicillin N,
isopenicillir. ~, penicillin V, or the like. Representative ex~
amples of the semi-synthetic penicillins may be carbenicilline
: :' .
(i.e. a-carboxybenzylpenicillin), cloxacillin (i.e. ~3-(o-chloro-
phenyl)-5-methyl-4-isoxazolyl]penicillin), dicloxacillin (i.e.
~ -(296-dichlornphenyl-5-methyl-4-i~oxazolyl]penicillin), o~a-
cilline (i.e, (5-methyl-3-phenyl-4-isoxazolyl)penicillin), methi-
c~llin (i.e. (2,6 dimethoxyphenyl)penicil-in), propicillin (i.e.
a-phenoxypropylpenicillin) 9 phenethicillin (i.e. a-phenoxyethyl-
penicillin)9 ampicillin (i.e. D(-)-a-aminobenzylpenicillin),
~luclo~acillin ~i.e. [3-(6-fluoro-2-chlorophenyl)-5-methyl-4-
iso~azolyl]penicillin), sulbenicill1n (i.e. a-sulfo-phenylacet-
amidopenicillin), amoxycillin (i.e. D(-)-a-amino-(p-hydroxyphenyl)-
acetamidopenicilIin~, or the like and their ~alts. ~;
The salt~ of the pen~cillin compound~ (II) are exempli~~ied the same examples as those of cephalosporin compound (I).
Preferred combinations of the cephalosporin compound~
and the penicillin compounds are a combination of a cephalo-
~porin compound ~elected from the group consisting of cefazolin,
5 -- .
- ''
. , ,
;, .
37~ :
FR-10123 and FR-10675 and a penicillin compound selected
from the group consistin~ oL carbenicillin, cloxacillin, di-
cloxacillin, oxacillin, methicillin, propicillin, phenethi-
cillin, ampicillin, fluclo~acillin, amoxycillin and sulbeni-
~illin. The most preferr~d eombinations are ce~azolin/carbeni-
cillin, cefa7.01in/clo~acillin, cefazolin/dicloxacillin~ FR-10123/
~lucloxacil~in and ~R-10675Jamoxycillin.
- The ratio of the cephalosporin compound or its salt
and the penicillin compound or its salt in the present anti-
bacterial composition may vary with the compounds to be combined
respectively, the ~ind~ o~ the bacteria and the symptoms of the
infected animals to which the present composition i9 applied,
but may usually be in a range of 1 1 to 1 : 10 by weight, pre- ~ -
~erably 1 : i to 1 : 4 by weight. --~
... . : . .. . . .
The antibacterial composition of the present inven-
tion is useful for treætin6 and preventing diseases induced by
pathogenic bacterla in anlma~ls other than human, for instance,
poultry, domes~ic animals, pet animals, or experimental ani-
mals (e.g. chicken, turke~, duc~., quail, cow, cattle, horse, -
~ pig, hog, dog, sheep, goat, mink, canary, macaw, mouse, rat or
- rabbit).
.
~ he present antib~cterial composition may be applied
to the animals in conventional forms which the conventional
cephalosporin preparations and penicillin preparations are
a~plied to. ~or instance, it is preferably applied in a form
o~ in~ection, and for treating mastiti~ in cow or other ani-
male, it i3 preferably a~plied in a form of infusion. It may
be also be applied locally in a form of a powder or an oint-
ment. When u3ed a~ an in~ection or infusion, it may be u~ed
in admi~ture with a solid or liquid carrier or diluent .~hich
- 6 -
"
~ i3~759
i~ u~ually u~ed for the conventional antibiotic injections or
infusions. The most preferred carrier or diluent is water~
vegitable oils, ~ara~fin~ or the like. ~lhen used a~ an oint-
ment, it may be used in admixture with conventional oint~ent
bases.
The dosage o~ the pre~ent composition Jill vary with
the kinds of the cephalosporin compounds and the penicillin
, . ..
compounds and the mixed ratio thereof as well as the ~inds and ~
. , , , , ~ ,
the severity of the infection. For instance, for treating ~ov-
vine mastiti~ during lactation drying period, it may be adminis-
tered in a dose of about 200 mg/quarter.
The antibacterial activities and the preventing effec-
:
tiveness aga~nst bacteial infection of the present compositon
are illustrated by the following experimental tests in vitro and
in VlVO.
~t 1
_, ~
~ynergi~tic activity of cefazolin and cloxacillin
.. - :
against pathogen isolated from milk o~ cow suffering from mastitis
, , ~ .
i~ the inhibitory concentration test in ~itro~
In a heart infusion medium containing a prescribed
amount of cloxacillin and cefazolin sodi~n (hereinafter, re-
~erred to merely as "aefazolin" was inoculated each pathogen ~/ -
ln a concentration of about 105 cells/ml, and it was.cultured
at 375C ~or ~0 hours, and then the growth of the test micro-
or~anism3 wa~ mea~ured. The result~ are shoT~n in the follow-
ing table In the tables, the symbol "+" means that the test
microoreani~m ~rew and the symbol "-" means that the test
microor~an~sm did not erow.
- 7 -
~:3387~ :
Table_l ~Escherichia coli, strain 4U-58-2L~) .
Cloxacillin
(mcg/ml) ____l_____ . . :
5 _ _ _ _ . .
f _ _ :~
12.5 - ~ - ~ _ ::~
6.25 + + .+ _ ;
. o + _ _ L~ . ~ ~ .
:
0 0.39 0,78 1.56 -
Cefazolin ~mcg/ml)
Table 2 (Escherichia coli, strain 8-29-RB) .
,... - .
Cloxacillin
(mcg/ml) _ .
100 ~ __ _ .-
~ _ ~
~ ~ 50 : ~ ~ _ _ _
_ _ _ .
+ * r-~~~ ~ ~ I;
12.5 + + + _ _
_, ~ ..
6.25 + ~ + _ _
3.13 + + + _ ~ :
:--
O, + L~ +_ , +
. 0: .3g0.7~ 1~56 3.13
Cefazolin (mcg/ml)
~ .
: ~ .
~:
,
, ,, :
. .
,
;'. . .
10;3B759 ¦:
Table 3(Proteus mirabllis, strain 48-~2~F) :
Cloxacillin ~
(m4go/ml) _ _ _ I ; ' ~:
200 _ + _ _ _ . ~
100 + + ~__ _ , `,',,~
5o + + ~ ;
~ , }, .
+ + ~ + _ . ~
__ . ' ,~
12.5+ + + + _ ~ -:
...
6.25 + + + + _ ::~
_~ . .,:' . ,
O ,+ ,+ ~ + + . ,~ '",''
0 0.78 1.56 3.1~ 6.25 ~-
Cefa~olin (mcg/ml)
Test 2
~ ~ Synerglstic activ1ty of cefazolin and~cloxacillin
:~ against pathogen isolated from dogs suffering from diarrhea in
: the inhibitory concentration~test in vitro: : ,~
In the aame manner as described in Test 5, the test
~as~carried out with Salmonella spp.~isolated from rectum feces
;~
of diarrhea dogs. ~he results are shown i.n the following tables. .~: :
almonella t2~____ rium, strain Dl55)
Cloxacillin :~
(mcg/ml) r--~ I .
200 + _ _ I _ _
_ : ~ - _
'~.: ,100 , + +_ _ _ ; - , '~
: . 50 + ~ + + _ j
_ "
25 + + + + _ .
,. -- .,
f 12,5 ~ + I + ~ +
6.25 + + + ~ .
i ~,;
, O + + + I + ~ , .
. __ l :
0 0.20.39 0.78 1.56
Cefezolin (mcg/ml) :
,,, , ,
,; ,~",
.', _ 9 _ ~;
',, '
.'
" . , , , ~ , . .
~:
,, 1 i
,'' ,' ~ ' , ' ,
,. . . .
-~ ~~38~7S9 :-
Table 5 (~almonella enteritidi~, ~train 1892)
Cloxacillin
( ms_/m )
12.5 ~ + + +
6.25 + + + + `
~ ' . O _ __ _ . ''~'-"':'
0 0,78 1.56 3.1
Cefazolin (mcg/ml)
Test
Effects on the ex~perimentally infected mice: -
ICR male mlce of 4 weeks age (10 mice per~one group)
~were used. A prescribed amount of the pathogenic bacteria
:~ , .
suspended in~5 ~,' mucin was lnoculated intraperitoneally. One
hour after the inoculation, the antibiotics as~ mentioned in
the ~ollowing table were administered subcutaneously, and ~;~
; ~hen-the inhibitory effects thereof were measured. The re- ~ - =
sults are shown in the following table. 1~;
.
!:
;
1"'-~
` ' ~',:
''" "
. . ,
- 1~ - ., '
'''''' ' ' ''' ' ' ,
~,......... .
~"' ' ''' '' ,
Table 6 ~ 75g
_ _ . ~ , .,
ED~o m~/mouse ~
, _
Micro- Cbalenge Calbeni- ¦
or~anisms dose Cillin ~ lcefa~olin Calbeni-
inoculated (cell~/mouse) Cef~lzol nl c 1 n
Escherich~a . ::
c~ strain ~.6 X 105 1.12 1.60 3.85 :
_ _ ~ . . . . _
Proteus 1.2 :C 108 ¦ 0.60 ¦ 0~90 ¦ 1.11 -~
~train-5~26 j
. . . ..
C trob traln~ 8.1 X 10 ¦ 12.~ l > 20 ¦ .
815 ~
. Citrobact~r , .
spp., strainl 4.8 X 104 3.28 7 11 > 20
. .
,; .
As made clear from the above results, the synergistic : -
i~hibitory activity of carbeniclllin sodium and cefazolin ~as .
also confirmed by in vivo test~ . v . . :~
-~ Test 4
Synergistic activity of cefazolin and cloxacillin
against pathogen isolated from milk of cow su~fereing from
.
ma~titis in the inhibitory concentration test in ~vitro:
.
In the same manner as described in Test 5, the test
. wa~ oarried out with Serratia epp., strain 22 being resistant ;~
to cephalosporins and penicillins and Staph~lococcus aureus~ .-
~train 7 originated bovine mastitisO The results are shown
ir the followina table-. ~
`.
. .
-ç
. _
r
.' . I
; .
37~9
Table_7 (Serratia spp., ~train 22)
Clo~acillin
( ~COgO/n`'l ) _ _
l ~ ~ , . ~
200 + + _ _ _ _ ~ _
_ _ ~ I _.
100 ~. + ~ I - ! -
__ _ _ __
5 + ~ + I + I _ _ _ _ ~
I _ ~ ~ ~
25 + + I ~ + l + +
__ ~
~2.5 rL ¦ + ¦ + + + ¦ Lr
_ _ __ __
6.~5 + ¦ + + rL ~Lr ¦ -Lr ¦ + ¦ _ ¦ .
~ ~ ~ I _ . ~ ,
o~r ~lL~rL ¦ ~ ¦ + ~ ~ ¦ + +
------ - ~ - - ~ --
0 . 6.2512.5 25 50 100 200 400 . 800
Cefaæolin (mcg/ml)
.. . . ~ . ,
T~ble 8 (Staph~ococcus aureus~ strain 7) ~ :
Cloxacillin
tmcg/ml) , -
0 2 + ~ + I _ _ -~-:
~ . , I _~ - ,_ - .' .-
- C).l + 1 + 1 + ~ + I .
: ~ :
0-05 + ¦ -Lr ¦ + ~ ~
.~ ~ . _. ~ ~ ~ __ I I `'
- 0.025 + ¦ ~ ¦ + ¦ ~rL + I +
~ ~ - -t - t-- I - -------r- l :
. - O ' + I + I + I t + I
0, 0.025 0.05 0.1 0.2 0.4 ..
- Cefazolin (mcg/ml)
- ~ est 5 '
The synergistlc activity of FR-10123 and flucloxacil- .
lin against Serratia spp,, ~train 22 isolated from bovine mastitis ~-
was tested in the same manner as described in Test 1, wherein
the pathogen wa~ lnoculated in the medium in a concen~ration of
105 cells/ml. The result3 are shown in the following Table.
, - 12 - -
., ~
7S~
Table 9 (S~E~ 5p~. 9 ~train 22)
Flucloxacillin
(mcg/ml~ ~ _ I
200 ~ ~ _
100 ~=_ = .,
~0 ~ ~
~ _ I I .,
I +_ I + _l + I + I + ~ ~ ~
12 5 + + I + l ~ l + l +
i ,
6.25 + ~ I + I ~ + I + I ~
~ __ _ _ j I ,
o .+ + l + l ~ + l + + l ~ ~ + .
_~ ~ _................ ;
~: 0 6.25 12.5 25 50 100 200 400 800 : :
~R-10123 (mcg~ml)
Tes~ 6 .
- The syner~istic activity o~ FR-10675 and amo~ycil-
lin against Sta~hvlococcus aureus, strain ~ isolated from mil~
o~ ~ow suffering from mastitis was tested in the same manner -~
~ . . - ,
as described in ~`est 1, wherein the pathogen was inoculated in ~ ~:
: the medium in a concentration o~ 106 cells/.ml. The results are .
: : shown in the following Table.
Table 10: (5ta~hvl-ococcus auIeus~ strain 8)
Amoxycillin :
(mcg/ml)
- 6.25 _ _ 3
.13 ~ + + _ _
.56 _ ~ + +
0c78 + + + + . . .
0.39 + + ~ ~. .
_ _
O +. ~ + + .-~ - .
,. _ ._ . ...
g 0.1 0.2 0.39
' FR-10675 (mcg/ml) .. ~ :
The antibact~rial compo3ition~ of the present in- :
~entlon are illu~trated by the follouing ~xample.
: 3
il7S9 ~ ~
- Exam~le 1
Cefnzolin sodium 100 m~
Cloxacillin 100 mg
~anette llax SX (tradename) 50 mg
Soft paraffin 100 mg
Brilliant b~ue ~CF 25 mg :;
~h~ above ingredients were mixed ~ith liquid paraf-
fin to give a total weight of 3 g per infusion preparation.
xample 2
Cefazolin sodium 40 mg .~:
Clo~acillin 150 mg ¦ ;
~anette Wa~ SX (tradename) 50 mg~
- Soft paraffin 100 mg
rilliant blue ~C~ 25~mg
- ~he above ingredients were mi~ed with liquid paraf~
~, :fin to give a total weight of 3 g per infu~ion preparation.
,,
~. ,
: ' - '
'
.
: - 14 -
~" :''''''' '''T
.",